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Abstract:  Background: Limited data is available about the effects of hemodialysis sessions, coronary artery disease 
(CAD), and diabetes on serum cardiac troponin T (cTnT) levels in patients with end-stage renal disease (ESRD). 
Objectives: To test whether hemodialysis could be associated with an increase in cTnT concentration. To evaluate if  
coronary artery disease (CAD) or diabetes are associated with higher cTnT levels in ESRD. 
Methods: Serum cTnT levels were measured immediately before and after dialysis 3 times over 1 year (0, 6, and 12 
months). 
Results: A total of 100 ESRD patients without acute coronary syndrome (mean age of 58.5 years, 34% with diabetes, and 
37% with CAD) gave 267 pre-dialysis and 260 post-dialysis blood samples. The mean (standard deviation) pre-dialysis 
cTnT levels were 0.06 (0.12), 0.05 (0.06), and 0.07 (0.07) mcg/L at 0, 6, and 12 months, respectively. The post-dialysis 
cTnT levels were similar on average. Among 259 samples with cTnT measured both before and after dialysis, 79 (30.5%) 
showed a decrease in serum cTnT, 97 (37.5%) showed an increase and 83 (32%) showed no change following dialysis. 
Mean cTnT was higher in CAD than in non-CAD patients. We observed no significant difference in mean cTnT levels  
between diabetic and non-diabetic patients. 
Conclusions: cTnT levels were not affected by individual hemodialysis sessions, and remained stable around 0.06 mcg/L 
over a 1-year period in ESRD patients. Random cTnT levels were higher in stable CAD patients undergoing hemodialysis. 
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INTRODUCTION 
  Cardiovascular mortality in patients on chronic hemo-
dialysis is 10 times higher than that of the general population 
[1]. Elevated cardiac troponin T (cTnT) is a marker of   
myocardial cell damage and is associated with a higher car-
diovascular risk [2, 3]. It has become the biomarker of 
choice for the diagnosis of myocardial infarction [4]. More 
than 10 years ago, elevations of cTnT were reported in   
patients with chronic kidney disease (CKD) [5]. The debate 
about the interpretation of elevated cTnT in the presence   
of abnormal renal function is still ongoing. CKD patients   
are at risk for silent ischemia [6]. In a specific patient, it is  
at times difficult to distinguish elevated cTnT due to an   
acute coronary syndrome (ACS), especially in the context   
of atypical symptoms, from those elevation presumably   
associated with CKD, which do not mandate acute cardiac 
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care. Nevertheless, elevated cTnT levels in end-stage renal 
disease (ESRD) patients have their own clinical relevance 
since they have consistently been found to be predictive of 
increased mortality [7-9] There is limited information on the 
short- and long-term effects of hemodialysis on serum cTnT 
levels [10]. Hemodynamic stress associated with dialysis 
could be associated with a transient increase in serum cTnT 
concentration and repeated hemodialysis sessions could lead 
to a progressive increase in serum cTnT over time. Coronary 
artery disease (CAD), diabetes, congestive heart failure   
and left ventricular hypertrophy have been linked to higher 
serum cTnT levels in chronic renal failure patients and in  
the general population [11, 12]. To interpret an elevated   
serum cTnT level in an individual CKD patient, knowledge 
of the magnitude of the changes in cTnT that can be   
expected from his baseline condition would be useful. We 
also evaluated the impact of CAD or diabetes on cTnT levels 
in these patients. 
METHODS 
Research Objectives 
  The primary objectives were to evaluate the mean serum 
cTnT level before and after a hemodialysis session and the 
change in serum cTnT level associated with a hemodialysis 70    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Mongeon et al. 
session, and to determine the variation in serum cTnT levels 
over 1 year in a population of ambulatory stable ESRD   
patients who were not admitted for an ACS during follow-
up. We also sought to assess the prevalence of cTnT  0.07 
mcg/L (above the threshold for myocardial necrosis at our 
institution) in an unselected population of ESRD patients. A 
secondary objective was to determine the effect of CAD and 
diabetes on serum cTnT levels in ESRD patients. 
Study Population 
  The protocol was approved by our institutional research 
and ethics committees. A series of 139 consecutive   
hemodialysis patients treated at Notre-Dame Hospital, one of 
the hospitals of the Centre Hospitalier de l’Université de 
Montréal, were asked to participate in the study. All patients 
who agreed provided informed consent. Inclusion criteria 
were that the patient had ESRD requiring chronic   
hemodialysis, was 18 years of age or older, and was able to 
understand and sign the consent form. Patients were   
excluded from the present analysis if they presented an ACS 
during the 1 year follow-up, because they could no longer be 
considered stable from a coronary standpoint. 
Data Collection and Definitions 
  Hospital charts and dialysis records were reviewed to 
collect relevant clinical and laboratory data by one of the 
authors (FPM). Patients were interviewed at enrolment by 
the same investigator. A written survey about the occurrence 
of chest pain or hospitalization in the 2 preceding weeks was 
administered before each blood samples were taken. CAD 
was considered present when we could identify a previous 
myocardial infarction, a previous surgical or percutaneous 
coronary revascularization, the presence of inducible   
ischemia on a stress test, or at least 1 coronary stenosis > 
50% on any past coronary angiography. We used a sensitive 
definition of an ACS; it was considered whenever the patient 
was admitted with symptoms or signs that were thought to be 
attributable to a cardiac cause, with or without elevated 
cTnT, with or without ECG changes. Subjects were consid-
ered diabetic if they had a history of diabetes mellitus or if 
they were undergoing therapy with oral hypoglycemic agents 
or insulin. 
Measurement of cTnT and Follow-up 
  cTnT levels were measured before and after three   
pre-specified hemodialysis sessions; at enrolment, and at 6 
and 12 months post-enrolment. cTnT levels were assayed 
using a third generation Troponin T STAT assay by Roche 
Diagnostics (detection limits: 0.01-25.00 mcg/L) [13]. The 
clinical biochemistry laboratory at our centre has validated 
the following reference values for our population: normal 
serum cTnT is < 0.01 mcg/L and threshold for myocardial 
necrosis is  0.07 mcg/L .We acknowledge that the package 
insert for the Roche Diagnostics Troponin T STAT test   
suggest 0.10 mcg/L as a threshold for diagnosis of myocar-
dial necrosis [13]. Follow-up ended after the third cTnT 
sample was taken. 
Statistical Analysis 
  Pre- and post-dialysis mean and standard deviation were 
calculated for cTnT at enrolment, 6- and 12-month follow-
up. Pre- and post-dialysis values were compared with a   
t-test. For each pair of pre- and post-dialysis serum cTnT, the 
delta (post minus pre) was calculated and deltas were 
grouped in 0.05 mcg/L strata. To assess the variation in 
cTnT over 1 year in individual patients, we calculated   
the delta in pre-dialysis cTnT between enrolment and the   
6-month follow-up and between 6 and 12 months of follow-
up. Pre- and post-dialysis mean cTnT were computed in   
subgroups of patients and compared using paired t-tests.   
Pre- or post-dialysis mean cTnT in patients with CAD   
and diabetes were compared to pre- or post-dialysis mean 
cTnT in ESRD patients without these conditions using a   
2-sample t-test. Statistical analyses were performed using 
SAS software, version 9.1 (SAS Institute Inc, Cary, NC). 
Table 1.  Characteristics of Patients at Enrolment 
 n=100 
Age, in years, mean (SD)  58.5 (15.5) 
Female, %  44 
Weight, in Kg, mean (SD)  68.9 (19.1) 
Time on hemodialysis, in years, mean (SD)  5.2 (6.0) 
Hypertension, %  93 
Tobacco use (past and present), %  67 
Dyslipidemia, %  65 
Left ventricular hypertrophy, %  52 
CAD, %  37 
Diabetes mellitus, %  34 
Left ventricular ejection fraction, in %, mean (SD)  58.3 (14.1) 
Peripheral artery disease, %  29 
Cardiac dysrhythmia, %  22 
Previous stroke or TIA, %  20 
Valvular heart disease, %  20 
NYHA functional class 3-4, %  7 
Hemoglobin < 90 g/L, %  4 
Etiology of ESRD*   
Diabetes mellitus, %  25 
Renal transplant failure, %  20 
Primary glomerulonephritis, %  18 
Nephrosclerosis, %  12 
Congenital kidney disease, %  10 
Secondary glomerulonephritis, %  8 
Hypertension, %  5 
Chronic pyelonephritis, %  3 
Unknown, %  6 
Other kidney disease, %  20 
CAD = Coronary artery disease; NYHA = New York Heart Association; SD = Stan-
dard deviation; TIA = Transient ischemic attack; ESRD=end-stage renal disease. 
*Some patients had more than one etiology for their ESRD. Effect of Hemodialysis, Coronary Artery Disease and Diabetes  The Open Cardiovascular Medicine Journal, 2009, Volume 3    71 
RESULTS 
Baseline Characteristics 
  Out of 139 patients asked to participate in the study,   
107 patients provided informed consent. Seven patients   
were excluded because of the occurrence of an ACS during 
follow-up. The analysis was therefore performed on a   
sample of 100 stable hemodialysis patients. Table 1 presents 
the baseline characteristics of our population. As expected, 
this is a high-risk population based on the prevalence of   
major risk factors for cardiovascular disease. In this popula-
tion, 34 patients had diabetes and 37 patients had evidence  
of stable CAD. The etiology of ESRD is also shown in   
Table  1. Twenty-seven patients had more than 1 cause to 
their ESRD.  
Mean Serum cTnT Levels 
  A total of 267 pre-dialysis and 260 post-dialysis cTnT 
measurements were done. Mean serum cTnT was elevated in 
these ESRD patients. This was observed in the complete 
cohort and in either subgroups with or without CAD or   
diabetes (Table 2). In the complete cohort, mean cTnT (0.06 
mcg/L, both pre- and post-dialysis) was close to the thresh-
old value for the diagnosis of myocardial necrosis (0.07 
mcg/L at our institution). Serum cTnT was evenly distrib-
uted between the 3 diagnostic categories: below the detection 
limit of the assay (< 0.01 mcg/L), non-diagnostic elevation 
(0.01-0.06 mcg/L) and above threshold for myocardial   
necrosis ( 0.07 mcg/L) (Fig. 1a). Pre- and post-dialysis   
data were strikingly similar. About 30% of measured cTnT 
levels were above threshold for necrosis, both pre- and   
post-dialysis. Among these elevated cTnT levels, very few 
were very high, the majority being just above 0.07 mcg/L 
and below 0.25 mcg/L (Fig. 1b). 
Effect of Hemodialysis Sessions on Serum cTnT 
  Among 259 samples with cTnT measured both before 
and after dialysis, 79 (30.5%) showed a decrease in serum 
cTnT, 97 (37.5%) showed an increase and 83 (32%) showed 
no change following dialysis (Fig. 2a), suggesting random 
variation. 
Serum cTnT Levels Over Time During the 1-Year   
Follow-up 
  To determine whether cTnT levels change over time in 
an individual patient, we calculated the difference between 
two serum cTnT levels that were sampled 6 months apart in 
individual patients. Follow-up was complete in 78 patients. 
This reduction in the sample size was caused by 8 deaths, 3 
transfers to another dialysis center, 3 renal transplants, 7 
missing cTnT measurements and 1 voluntary withdrawal. 
Since we could not show a difference between pre- and post-
dialysis values, we used pre-dialysis serum levels for this 
analysis. The first 6-month period is shown in Fig. (2b). The 
magnitude of the serum cTnT 6-month delta was small, as it 
was below ± 0.05 mcg/L in the majority of patients. Fig. (2b) 
also shows a near normal distribution of cTnT deltas. We 
present the same serum cTnT deltas for the second 6-month 
period of our study in Fig. (2c). Of note, in this last 6-month 
period, there were more patients showing a small rise in 
cTnT. Overall, it appears that the expected variation of   
serum cTnT over a 1-year period in individual hemodialysis 
patients is within ± 0.05 mcg/L. 
Effects of CAD and Diabetes on Serum cTnT 
  Of 100 patients, 37 had chronic CAD. Fig. (3a) displays 
that, in stable patients with CAD, the mean cTnT were   
significantly higher than in patients without CAD. This   
is observed for most cTnT measurements, except for the 
post-dialysis cTnT at baseline. In our cohort, there were 34 
diabetic patients. Mean serum cTnT levels were not signifi-
cantly higher in these patients (Fig. 3b). 
DISCUSSION 
Elevated cTnT in Chronic Kidney Disease 
  One third of the measured cTnT levels were above 0.07 
mcg/L. Myocardial cell damage and consequent leakage of 
troponin into the plasma compartment can occur after many 
Table 2.  Comparison of Mean Serum cTnT Levels Before and After Hemodialysis; Complete Cohort, and Stratified by CAD and 
Diabetes Status 
    Enrolment  6 Months  12 Months 
   Before  After  p*  Before  After  p*  Before  After  p* 
n  98  95    89 90   80 75    Complete Cohort 
  0.06 (0.12)  0.06 (0.08)  0.43  0.05 (0.06)  0.05 (0.06)  0.50  0.07 (0.07)  0.07 (0.08)  0.67 
n  36  34    30 30   27 26    CAD 
  0.10 (0.17)  0.08 (0.09)  0.25  0.08 (0.06)  0.08 (0.08)  0.89  0.10 (0.07)  0.10 (0.08)  0.41 
n  62  61    59 60   53 49    No CAD 
  0.04 (0.06)  0.04 (0.07)  0.29  0.04 (0.06)  0.04 (0.05)  0.30  0.06 (0.07)  0.06 (0.08)  0.92 
n  33  32    30 30   30 29    Diabetes 
  0.09 (0.17)  0.06 (0.08)  0.17  0.06 (0.06)  0.05 (0.06)  0.13  0.09 (0.08)  0.08 (0.10)  0.44 
n  59  57    53 54   46 42    No diabetes 
  0.05 (0.07)  0.05 (0.08)  0.11  0.05 (0.07)  0.05 (0.07)  0.73  0.06 (0.07)  0.06 (0.07)  0.74 
CAD=Coronary artery disease; *p for comparison of mean cTnT before and after hemodialysis. Values for cTnT are mean (SD), in mcg/L unless specified. 72    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Mongeon et al. 
cellular injuries [11]. The relatively low levels of cTnT 
measured in patients with ESRD suggest that minor cell   
injury has occurred, with release of small quantities of the 
cytoplasmic form of cTnT. The evidence that reduced clear-
ance of troponins by the failing kidney fully accounts for 
their elevated levels is limited [14]. It has been proposed that  
reduced clearance of cTnT fragments partly account for the 
elevated levels detected by laboratory assays [15]. However,  
 
troponin levels do not seem to normalize with improved   
renal function after renal transplant [16]. The exact nature of 
the mechanism involved in myocyte injury and impaired 
excretion of cTnT remains to be better defined [14]. Only a 
few studies reported the proportion of hemodialysis patients 
with cTnT levels above threshold for the diagnosis of   
MI. There is significant variability in previously reported 
numbers, ranging from 18.6 to 46% of patients with levels 
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Fig. (1). Distribution of serum cTnT.  a) Distribution of serum cTnT before and after hemodialysis sessions according to diagnostic   
category: below the detection limit of the assay (< 0.01 mcg/L), non diagnostic elevation (0.01-0.06 mcg/L) and above necrosis threshold  
( 0.07 mcg/L); b) Breakdown of the distribution of cTnT levels before and after dialysis in 0.05 mcg/L strata, showing that elevated values 
remain close to the necrosis threshold (0.07 mcg/L). Effect of Hemodialysis, Coronary Artery Disease and Diabetes  The Open Cardiovascular Medicine Journal, 2009, Volume 3    73 
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Fig. 2. contd…. 
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Fig. (2). Effect of individual hemodialysis sessions and of time on serum cTnT. a) Change in serum cTnT levels after an individual  
hemodialysis session; b) Difference in pre-dialysis serum cTnT between enrolment and 6-month follow-up in individual patients; c)  
Difference in pre-dialysis serum cTnT between 6- and 12-month follow-up in individual patients.  
above threshold in studies that use a third generation   
assay [8, 12, 17-20]. The use of different thresholds for ne-
crosis may partly explain this wide range of values. Higher 
cTnT is associated with CAD but not with diabetes mellitus 
in our population. These results are similar to those from 
Conway et al., whose study design was similar to ours [21]. 
On the contrary, Iliou et al. found a strong association   
between high cTnT levels and diabetes mellitus [12]. Our 
results do show a tendency to higher cTnT levels in diabetics 
(Fig.  3b). Controversy remains since diabetes mellitus,   
has been incriminated as a cause of elevated cTnT in CKD 
[22, 23]. This could be caused by the accumulation of   
advanced glycation end-products in diabetic patients with 
ESRD [9]. 
Effect of Hemodialysis Sessions 
  Individual hemodialysis sessions did not have any   
substantial impact on serum cTnT levels in our population. 
To date, the few studies that used a third generation assay to 
measure cTnT did not find a difference between pre- and 
post-dialysis values, suggesting that cTnT is not filtered   
out of the plasmatic volume (Table 3). With 259 pairs of   
pre- and post-dialysis cTnT measurements in 100 patients, 
our study is the largest among those that used a third   
generation assay to demonstrate the stability of cTnT with 
dialysis sessions. The number of patients whose cTnT varia-
tion with individual hemodialysis sessions was above ± 0.05 
mcg/L was small (9 patients). All of these patients were   
either diabetic or hypertensive, had left ventricular hypertro-
phy or had sustained hypotension during a hemodialysis   
session close to sampling of cTnT (data not shown). In CKD 
patients, Han et al. [24] found that extreme variations in 
cTnT ( 0.10 mcg/L) within a single hospital visit are predic-
tive of short- and long-term cardiovascular events. 
Effect of Time 
  With complete follow-up to 1 year in 78 patients, our 
study is by far the largest to confirm that serum cTnT levels 
only present minor variations during a 1-year follow-up. Han 
et al. found that mean cTnT levels were higher when CKD 
patients where admitted for a cardiovascular event compared 
with their baseline levels [24]. Given that our objective was 
to predict the course of cTnT levels in stable ESRD patients, 
we excluded these patients. A baseline cTnT value would 
only be valid if one can be certain that it is not subject to 
strong variations over time. We believe our study provides 
such reassurance regarding the stability of baseline cTnT 
values in ESRD patients. Our data therefore support the rele-
vance of obtaining baseline cTnT values in CKD patients. 
Conway et al. showed that, in hemodialysis patients, cTnT Effect of Hemodialysis, Coronary Artery Disease and Diabetes  The Open Cardiovascular Medicine Journal, 2009, Volume 3    75 
started to rise between 8 and 15 months of follow-up. The 
rise exceeded 25% in half of the patients [21]. This is similar 
to our finding that more patients presented a small increase 
in serum cTnT during the second half of our study (Fig. 2c). 
Willging  et al. noted that a longer history of dialysis was 
associated with a higher cTnT level [25]. We found that   
extreme (> 0.05 mcg/L) variations in cTnT over 6-month 
periods were rare (9 patients). These patients either had   
diabetes, hypertension, or documented CAD, or were   
hypotensive during hemodialysis (data not shown). 
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Fig. (3). Effect of coronary artery disease and diabetes mellitus on serum cTnT. a) Mean serum cTnT levels before and after hemodialy-
sis sessions in patients with and without chronic coronary artery disease (CAD); b) Mean serum cTnT levels before and after hemodialysis 
sessions in patients with and without diabetes mellitus. *p < 0.05 for the comparison of mean cTnT in CAD vs. non-CAD patients and in 
diabetic vs. non-diabetic patients, respectively. 76    The Open Cardiovascular Medicine Journal, 2009, Volume 3  Mongeon et al. 
Clinical Implications 
  Our findings have several clinical implications. The   
possibility of a false positive diagnosis of myocardial infarc-
tion based on cTnT levels is a vexing situation for the   
clinician. Our data provide grounds for a clinical approach to 
elevated cTnT in ESRD patients based on knowledge of their 
baseline values. First, very high cTnT levels are rare in 
hemodialysis patients, with most values being far below 0.25 
mcg/L. Thus, caution is required before imputing to the 
CKD cTnT values that are above this threshold. Second, 
although its usefulness was not tested in our cohort, cTnT 
values could be obtained at 1 point in time in hemodialysis 
patients to allow for future comparison. The importance of 
baseline cTnT values was shown in the setting of percutane-
ous coronary intervention [26]. We have demonstrated the 
stability of cTnT values in stable ESRD patients without 
ACS, which ensures the validity of a baseline value. Our 
data also show that cTnT can be sampled at any time with 
respect to hemodialysis. Since we have documented the   
stability of cTnT in a time frame of 12 months, consideration 
could be given to repeating baseline cTnT annually. Baseline 
cTnT may be particularly useful in patients with known 
CAD, in who elevated baseline cTnT values are more likely 
to be measured. 
Strengths and Limitations 
  Notable advantages of our study are its prospective   
design and the fact that we have the largest cohort to date in 
which we were able to measure pre- and post-dialysis cTnT 
with a third generation assay and to follow them over time. 
However, our study is limited by the fact that we may have 
missed a late rise in cTnT by sampling immediately after 
hemodialysis, since a rise in cTnT can occur up to 8 h after 
an index event. It was obviously not feasible to ask the pa-
tients to stay for hours after their hemodialysis session. 
However, if such a rise occurs frequently, we believe some 
of the pre-dialysis samples would have reflected it. Yet, 
these values were stable over time. We also did not adjust 
cTnT levels for hemoconcentration following dialysis   
and for Kt/V. Kt/V is the clearance of urea, normalized to  
its estimated volume of distribution, which measures the 
adequacy of dialysis [27]. A lack of adjustment for hemo-
concentration would cause a false elevation of serum cTnT 
following dialysis, which was not observed in our data. Our 
study is also limited by a reduction of sample size during 
follow-up due to missing cTnT samples at 1 or more of the 
pre-specified sampling time or due to patient deaths or trans-
fers. It is also limited to a 1 year follow-up; a longer obser-
vation could have highlighted longer-term rise in serum   
troponin, as previously documented by others [21]. Finally, 
there is a possibility that the 32 hemodialysis patients who 
declined participation were significantly different from the 
rest of the study population. 
CONCLUSIONS 
  cTnT levels were not affected by individual hemodialysis 
sessions, and remained stable around 0.06 mcg/L over a 1-
year follow-up period in this stable ESRD population. How-
ever, random cTnT levels were higher in stable CAD   
patients undergoing hemodialysis. 
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